Submission of Integrated Annual Report for the Financial Year 2025-26 along with Notice convening the 41st Annual General Meeting as per Regulation 34 of SEBI (Listing Obligations and Disclosure ....

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED CIN: L24233MP1985PLC002709 Registered Office: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.) Tel. 0731-2426700; Email id- bcplcompliance@gmail.com; Website- www.biofilgroup.net; Fax: 0731-2426700 Date: 26th August, 2026 To, To, The Secretary (DCS/Compliance), The Secretary (Listing/Compliance), Corporate Relationship Department, Corporate Relationship Department, BSE Limited National Stock Exchange of India Phiroze Jeejeebhoy Towers, Limited, Dalal Street, Mumbai-400001 Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051 Subject: Submission of Integrated Annual Report for the Financial Year 2025-26 along with Notice convening the 41st Annual General Meeting as per Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Reference: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Script Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014) This is to inform that the 41st Annual General Meeting (‘AGM’) of the Company is scheduled to be held on Wednesday, 23rd September, 2026 at 3.00 P.M. (IST) through Video Conference (VC)/Other Audio Visual means (OAVM), in compliance with relevant circulars issued by the Ministry of Corporate Affairs (‘MCA’) and the Securities and Exchange Board of India (‘SEBI’) as amended from time to time. In accordance with the aforesaid circulars issued by the MCA and SEBI, the Integrated Annual Report of the Company for the financial year 2025-26 along with the Notice convening 41st AGM is being sent through electronic mode to those members of the Company whose email address are registered with the Company and/or Depositories Participant(s) and for those Members who have not registered their e-mail address, a letter containing web-link of the website including the exact path, where details pertaining to the entire Annual Report is hosted is being sent at the address registered in the records of RTA/Company/Depositories. Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of an Integrated Annual Report of the Company for the financial year 2025-26 containing the Notice convening 41st AGM of the Company. The Integrated Annual Report for the financial year 2025-26 along with Notice convening the 41st AGM is also uploaded on the Company’s website at www.biofilgroup.net and the website of Central Depository Services (India) Limited at www.evotingindia.com. Kindly take the same on your record and acknowledge. Thanking You, Yours Faithfully, FOR, BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED APOORV JAIN COMPANY SECRETARY & COMPLIANCE OFFICER M.NO:A71739 Encl: a/a 41st Annual Report 2025-26 BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED Annual Report 2025-26 41ST ANNUAL GENERAL MEETING Day: Wednesday Date: 23rd Day o f September, 2026 Time: 3:00 P.M. Mode: Video Conferencing (VC) or Other Audio Visual Means (OAVM) Content Page No. Corporate Information 3 Notice of the 41 Annual General 4-25 Meeting Board’s Report 26-37 Annexure’s to the Board’s Report 38-44 Management Discussion and Analysis 45-47 Report Corporate Governance Report 48-73 Independent Auditor Report 74-83 Balance Sheet 84 Statement of Profit & Loss 85 Cash Flow Statement 86 Statement of Change in Equity 87 Notes to the Financial Statements 88-119 Page TROPER EDISNI Annual Report 2025-26 CORPORATE INFORMATION 1. Board of Directors: S. No. NAME DESIGNATION 1 Mr. Ketan Shah Chairman & Managing Director 2 Mr. Meet Shah Non-Executive Non-Independent Director 3 Mr. Ashok Kumar Ramawat Non-Executive Independent Director 4 Mr. Satish Beohar Non-Executive Independent Director 5 Mrs. Gayatri Padiyar Non-Executive Woman Independent Director 2. C6O MMIMTrT. ESEmSi:t esh Shah Non-Executive Non-Independent Director Audit Committee: Stakeholders’ Relationship Committee: Mrs. Gayatri Padiyar- Chairperson Mrs. Gayatri Padiyar- Chairperson MNor.m Aisnhaotkio Knu &m aRre Rmaumnaewraatt-i oMne Cmobmerm ittee: FMirn. aAnscheo kC oKmummairtt Reaem: awat- Member Mr. Satish Beohar- Member Mr. Satish Beohar- Member Mrs. Gayatri Padiyar- Chairperson Mr. Ketan Shah- Chairperson Mr. Ashok Kumar Ramawat- Member Mr. Meet Shah- Member M3.r K. SMaPti:s h Beohar- Member Chief Financial Officer: Company Secretary & Compliance Officer: M4.r A. PUaDvIaTnO SRinSg: h Rajput Mr. Apoorv Jain Statutory Auditors: Secretarial Auditors Maheshwari & Gupta Joshi Sahay & Company Chartered Accountants Company Secretaries 312-314, Manas Bhawan Extn., 11/2, RNT 122, Krishna Business Centre, 11, PU 4, Next to MInatregr,n Ianld Aorued -i t4o5r2s0:01 (M.P.) Medanta, Hospital, Rasoma Square, Indore - 452010 (M.P.) Sethiya Khandelwal & Co. Chartered Accountants 520. B9,A MNaKnEaRs SB:h awan Extn., 11, R.N.T. Marg, Indore - 452001 (M.P.) State Bank of India IDBI Bank Ltd. IDFC First Bank I6n. dLuisstterida la Et sSttaotec kB rEaxncchha, nIngdeos:r e Ratlam Kothi Branch, Indore Vijay Nagar Branch, Indore National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Tower, Dalal Street, Fort, Mumbai – B7.a Rndergais (tEearsetd), OMfufimceb:a i – 400051 400001 BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED CIN: L24233MP1985PLC002709 B/12-B, Industrial Estate, Pologround, Indore (M.P.) India, 452015 E8m. Raeilg: ibsctrpalcro &m Sphliaanrece T@ragmnsafiel.rc oAmge, Wnte: bsite: www.biofilgroup.net, Phone: 0731-2426700, 2723017 Ankit Consultancy Private Limited Plot No. 60, Electronic Complex, Pardeshipura, Indore-452010 (M.P.) Phone: 0731-4065797, 4065799 • Fax: 0731-4065798 Email ID: investor@ankitonline.com • Website: www.ankitonline.com Page Annual Report 2025-26 BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED CIN: L24233MP1985PLC002709 Registered Office: B/12-B, Industrial Estate, Pologround Industrial Estate, Indore (M.P.) 452015 Tel. 0731-2426700; Email id- bcplcompliance@gmail.com; Website- www.biofilgroup.net; Fax: 0731-2426700 Notice of the 41st Annual General Meeting NOTICE BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED st is hereby given that the 41 Annual General Meeting (AGM) of the Members of will be held on Wednesday, 23 day of September, 2026 at 3.00 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) for which purpose the Registered office o f the company shall be deemed as the venue for the Meeting and the proceedings of the Annual General Meeting sOhradlli nbaer dye Bemuseidn etos sbees m:- ade thereat, to transact the following businesses: 1. To consider and adopt the Audited Financial Statements of the Company together with the Report of the Board of Directors and the Auditors thereon for the financial year ended March 31, 2026. “RESOLVED THAT the Audited Financial Statements of the Company for the financial year ended 31 March, 2026 together with the Reports of the Board of Directors and the Auditors thereon and Management Discussion Analysis and Corporate Governance Report, as circulated to the members, be considered and 2. aTdoo apptepdo.”i nt a Director in place of Mr. Smitesh Shah (DIN: 00326182) who retires by rotation in terms of Section 152(6) of the Companies Act, 2013 and being eligible offers himself for re-appointment. “RESOLVED THAT subject to the provisions of Section 152(6) and Article of Association of the Company and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014, Mr. Smitesh Shah (DIN: 00326182), who is liable to retire by rotation at this Annual General Meeting and being eligible offers himself for re-appointment, be and is hereby re- Speacpipaol iBnutesdin aess as eNso:-n -Executive Non- Independent Director of the Company liable to retire by rotation.” 3. Continuation of directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-Executive Independent Director of the Company on attaining the age of 75 (seventy-five) [Showing first 8,000 characters — download PDF for full document]